The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
MSAID
Garching bei München, Germany
A
11-50 Employees
2019
Key takeaway
MSAID is a leader in proteomics artificial intelligence, utilizing advanced AI-based solutions to enhance the analysis and interpretation of proteomic data. Their expertise and innovative software could significantly improve computational approaches in drug discovery.
Reference
Product
MSAID | Software for Proteomics
As the leader in proteomics artificial intelligence, MSAID replaces current algorithms with powerful, AI-based solutions and paves the way for a deeper, and more reliable way of interrogating proteomics data.
Aladdin Blockchain Technologies
Berlin, Germany
A
11-50 Employees
2017
Key takeaway
The company, Aladdin Healthcare Technologies, leverages AI to accelerate the discovery of novel therapeutics and diagnostics for age-related diseases. Their proprietary AI solutions and multi-disciplinary team enhance the drug discovery process, making it more efficient and cost-effective.
Reference
Core business
Aladdin Healthcare Technologies – A.I assisted early diagnosis for age-related disease
Molecular Health
Heidelberg, Germany
A
101-250 Employees
2004
Key takeaway
Molecular Health is focused on leveraging artificial intelligence and data-driven technology to enhance drug development and patient outcomes. Their software solutions integrate human expertise with advanced analytics, providing healthcare professionals and therapy developers with high-quality data and insights that are crucial for personalized therapy decisions and overcoming challenges in the drug discovery process.
Reference
Product
Transforming Drug Development: Molecular Health Dataome
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
AICURA medical GmbH
Berlin, Germany
A
11-50 Employees
2018
Key takeaway
AICURA is dedicated to enhancing patient outcomes by transforming clinical drug development through a robust data and AI ecosystem. Their platform facilitates easy access to AI-ready clinical data, streamlining research processes, and optimizing drug discovery efforts.
Reference
Core business
AICURA medical
AICURA is transforming clinical research with data and AI. Streamline your processes and gain valuable insights with to improve the probability of success of your clinical prgrams. Explore how AICURA can accelerate your clinical research today.
Axolabs
Kulmbach, Germany
A
11-50 Employees
2007
Key takeaway
Axolabs specializes in the discovery and development of therapeutics, particularly focusing on DNA and RNA-based drugs, leveraging over 20 years of expertise in oligonucleotide research. Their integrated solutions encompass various disciplines, ensuring high-quality services that support the entire process from target identification to clinical development.
Reference
Service
Lead Identification / Axolabs
Targos Molecular Pathology GmbH
Kassel, Germany
A
51-100 Employees
2005
Key takeaway
Discovery Life Sciences is dedicated to accelerating the development of innovative diagnostics and treatments, emphasizing their commitment to precision medicine. They offer a vast biospecimen inventory and advanced multi-omic services, which are essential for driving progress in cancer and infectious disease research.
Reference
Core business
Accelerate Breakthroughs Because Patients Are Waiting® | Discovery Life Sciences
Our mission is to restore hope by speeding the development of innovative diagnostics and effective treatments to improve care.
p.AI
Berlin, Germany
A
1-10 Employees
2020
Key takeaway
The company specializes in innovative solutions for the pharmaceutical industry, particularly in drug safety and pharmacovigilance. Their L2AI software addresses the challenge of processing large volumes of adverse event reports, utilizing data science techniques like natural language processing and statistical analysis, which could be relevant to advancements in AI drug discovery.
Reference
Service
Service - pharma.AI
Our team has extensive experience in L2A case processing; coding, data entry, quality control, reporting of ICSRs from all potential sources; creation and update of PSURs/ACOs/RMPs and their submission (CESP, eCTD). In the context of signaling, we also have expertise in literature review and processing of MLM cases. With our data driven approach, we tackle complex business processes, such as the processing of L2A cases, by transforming them into a digital solution through the use of natural language processing, forecasting, statistical analysis and active learning. By involving experts from the very beginning and in every step of the development process, we ensure a high quality standard and a customer- and solution-centred development.
Arcas
Berlin, Germany
A
1-10 Employees
-
Key takeaway
Arcas is a precision oncology therapeutics platform that utilizes advanced AI technology to enhance drug discovery and diagnostics in oncology. By integrating clinical, genomic, and pharmacological data through a multi-level deep learning approach, Arcas improves the predictive power of pre-clinical drug screening and develops precise biomarkers for clinical trials.
Reference
Product
Solutions — ARCAS – AI for precision oncology
Sciomics - Enabling Precision Medicine
Germany
A
11-50 Employees
2013
Key takeaway
Sciomics is at the forefront of Precision Medicine through advanced protein profiling and a robust biomarker signature pipeline, which is essential for innovative drug discovery. Their scioDiscover microarray platform enhances research from basic discovery to pharmaceutical R&D, supporting the identification and verification of novel drug targets.
Reference
Service
Novel drug targets – Discovery & Verification | Sciomics
IMAX Discovery GmbH
Dortmund, Germany
A
1-10 Employees
2010
Key takeaway
AXXSense is focused on the discovery and development of new bioactive molecules, including innovative flavors and cosmetic actives, through advanced screening and profiling of natural and synthetic compounds. With a commitment to tailored solutions and strategic partnerships, AXXSense supports its clients in identifying novel ingredients that can enhance their products.
Reference
Core business
IMAX Discovery GmbH | Research driven biotechnology company
At IMAX Discovery we develop flavors, fragrances and taste compounds for the food, beverage, pet food, cosmetic and perfume industry clients.
Technologies which have been searched by others and may be interesting for you:
The AI drug discovery industry in Germany is influenced by several key considerations. Regulatory frameworks are crucial, as the European Medicines Agency (EMA) and national authorities impose guidelines on drug development processes, including AI applications. Compliance with data protection laws, such as GDPR, is also vital, given the sensitivity of health-related data. Researchers and businesses should be aware of the challenges associated with integrating AI technologies into traditional drug discovery workflows, which may include resistance from established pharmaceutical practices and the need for substantial investment in technology and talent. Opportunities in this sector are significant, driven by Germany's strong pharmaceutical base and commitment to innovation. Collaborations between academia and industry can enhance research, while Germany's robust startup ecosystem fosters the development of novel AI solutions. Environmental concerns are gaining importance, particularly as sustainable practices become integral to pharmaceutical development. The competitive landscape is marked by both established pharmaceutical companies and emerging biotech firms, creating an environment ripe for innovation. Additionally, Germany's strategic position in the European market enhances its relevance on a global scale, making it an attractive hub for AI drug discovery initiatives. Understanding these factors can provide valuable insights for anyone looking to explore the dynamics of this evolving industry in Germany.
Some interesting numbers and facts about your company results for Ai Drug Discovery
Country with most fitting companies | Germany |
Amount of fitting manufacturers | 408 |
Amount of suitable service providers | 386 |
Average amount of employees | 11-50 |
Oldest suiting company | 2004 |
Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for Ai Drug Discovery
What are related technologies to Ai Drug Discovery?
Based on our calculations related technologies to Ai Drug Discovery are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Ai Drug Discovery?
The most represented industries which are working in Ai Drug Discovery are Biotechnology, IT, Software and Services, Other, Pharmaceuticals, Healthcare
How does ensun find these Ai Drug Discovery Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.